What is Immunocore?
Founded in 2008 and headquartered in the United Kingdom, Immunocore is a pioneer in the development of biological drugs utilizing soluble T-cell receptor (TCR) technology. By engineering molecules that can redirect the immune system to identify and eliminate diseased cells, the company addresses critical unmet needs in oncology, autoimmune conditions, and infectious diseases. Its market position is defined by a sophisticated R&D pipeline and a commitment to precision medicine, which has attracted substantial institutional backing from global life sciences investors and strategic partners alike.
How much funding has Immunocore raised?
Immunocore has raised a total of $822.1M across 4 funding rounds:
Series A
$320M
Series B
$130M
Series C
$75M
Stock Offering
$297.1M
Series A (2015): $320M with participation from woodford investment management, eli lilly and company, Malin Corporation plc, and RTW Funds
Series B (2020): $130M led by RTW Investments, WuXi AppTec, Eli Lilly and Company, Rock Springs Capital, General Atlantic LLC, Bill & Melinda Gates Foundation, Terra Magnum Capital Partners, China Construction Bank, and JDRF T1D Fund
Series C (2021): $75M supported by BlackRock
Stock Issuance/Offering (2021): $297.1M, investors not publicly disclosed
Key Investors in Immunocore
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, providing both capital and deep scientific expertise to support transformative companies.
Eli Lilly and Company
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, and commercialization of prescription medicines, with a strong focus on oncology and immunology.
General Atlantic LLC
General Atlantic is a global growth equity firm that provides capital and strategic support to high-growth companies in the healthcare and life sciences sectors to accelerate international expansion.
What's next for Immunocore?
Following its recent capital infusion, Immunocore is well-positioned to accelerate its clinical trial programs and expand its therapeutic reach. The strategic deployment of these funds will likely focus on scaling manufacturing capabilities and advancing its lead candidates through late-stage regulatory milestones. As the company transitions into a more mature commercial phase, the focus will remain on leveraging its TCR platform to establish new standards of care, potentially unlocking significant value for stakeholders while addressing global health challenges through transformative scientific innovation.
See full Immunocore company page
